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Results: Differences in demographic and prognostic features (age, T 
stage, Gleason score, pre-treatment PSA, ADT) were not significant. 
 
 
Figure 1 compares time-incidence curves generated using the 1st, 2nd 
and 3rd quartile D90 levels as cut-off points. A progressive, dose 
related increase in biochemical control of disease is seen with 
increasing D90. FFbR was significantly higher in patients whose D90 was 
≥ the median value compared to D90 < median (p = 0·006). Similar 
findings were seen for V100. 
 
Table 1 shows 5-year FFbR rates for D90 and V100. In multivariate 
analysis D90, (p = 0.004), V100 (p = 0.0004), PSA (p = 0.03) and ADT (p = 
0.01) were significant covariates for risk of relapse. 
Conclusions: Dichotomising the data using 6 levels of response (above 
and below Q1, Q2 and Q3) showed a clear dose response with 
progressive and continuous improvement in biochemical control of 
disease across the entire dose (and volume) range. The data show that 
a minimum D90 of 108% of the prescribed dose should be the target to 
achieve. Implant quality is an important predictor of outcome after 
HDR brachytherapy. 
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Purpose/Objective: This retrospective study was performed to 
compare different boost techniques after breast conserving therapy 
(breast conserving surgery followed by whole breast irradiation) in 
terms of local and loco-regional recurrences. 
Materials and Methods: From 2000 to 2005, 1576 patients were 
treated with breast conserving therapy for in situ or invasive breast 
cancer. An electron boost (EB) was performed for a superficial boost-
volume (less than 29 mm under the epidermis), in all other cases a 
brachytherapy boost (BTB) was proposed. When patients refused a 
BTB or a BTB was not possible because of technical reasons, a photon 
boost (PB) was given. 75.8% (1195) of the patients received an EB 
after whole breast irradiation (WBI). 16.3% (257) of the patients were 
given a BTB (either with LDR or PDR) and only 5.6% (89) of the 
patients had a PB. The primary endpoints were local and loco-regional 
recurrences. Secondary endpoints were metastasis-free survival and 
overall survival, taking into account patient and treatment 
characteristics. 
Results: The median follow-up for all patients was 8.9 years in 
invasive cancer and 8.8 years in in situ cancer. Of the 1381 invasive 
breast cancer patients, we observed 35 (2.5%) local and loco-regional 
recurrences. Five- and 10-years relapse-free survival rates were 98.8% 
and 96.9%. Five- and 10-years overall survival rates were 95.1% and 
86.2%. We found no significant differences between the three boost 
techniques with respect to relapse risk or overall survival. The 
metastasis-free survival was longer in the EB group (90.7% at 10 years) 
and the BTB group (87.3% at 10 years) than in the PB group (82.7% at 
10 years). This difference was not significant anymore after correction 
for tumor stage (pT) (p=0.09) or lymph node stage (pN) (p=0.1). Of the 
195 patients with an in situ carcinoma, we found one local and one 
loco-regional recurrence. Five- and 10-years overall survival rates in 
this group were 99.5% and 93.8%. 
Conclusions: In women treated with breast conserving therapy 
followed by a boost irradiation to the tumour bed, the local and loco-
regional recurrences at 10 years in our institution are very low for 
invasive as well as for in situ breast cancer. No difference in 
recurrence was observed comparing the three different boost 
techniques.  
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Purpose/Objective: There is currently limited evidence for HR CTV 
dose planning aims in locally advanced cervical cancer. This study 
analyses dose-response for local control in image-guided adaptive 
brachytherapy (IGABT). 
Materials and Methods: RetroEMBRACE is a retrospective study with 
796 locally advanced cervical cancer patients treated in 12 institu-
tions by IGABT using GEC ESTRO guidelines. In 592 patients data was 
available on local status, HR CTV dose and volumes. FIGO stage distri-
bution was IB (19%), IIA (7%), IIB (50%), IIIA (3%), IIIB (18%), IV (3%). 
IGABT was combined with 45-50Gy whole pelvis EBRT and weekly 
cisplatinum (76%). IGABT was based on MRI (81%) or CT (19%), and was 
administered as high dose rate (HDR) (60%) or pulsed dose rate (PDR) 
(40%). Patient groups were formed according to 1) tumour width at 
diagnosis (cut-point 50mm), 2) HR CTV volume (cut-point 35cc), 3) 
stage (IB, IIA-IIB, III-IV), 4) histology (SQ versus AC+AdSq), and 5) dose 
rate (HDR versus PDR). HR CTV D90 dose-response for local control 
was evaluated in each sub-group by logit analysis. Dose for 90% and 
95% local control (TCD90 and TCD95) was determined. 
Results: At a median follow up of 31 (3-150) months, 48 local failures 
have been observed. HR CTV volume was 35cc±24cc and HR CTV D90 
87Gy±14Gy. A significant (p<0.05) dependence of local control on D90 
for HR CTV was found in the entire patient population (Figure 1) and 
in all subgroups except PDR (p=0.07) (Table 1). Logit analysis was not 
performed in stage IB due to limited number of events: 2/32 (6%) and 
0/83 (0%) local failures above and below 80Gy, respectively. In the 
'favourable' subgroups 'width<50mm', 'HR CTV volume<35cc' and 'stage 
IIB', local control >95% was seen for HR CTV D90 larger than 87Gy, 
85Gy and 93Gy, respectively. In the 'unfavourable' subgroups 
'width>50mm', 'HR CTV volume>35cc', 'IIIA, IIIB, IVA', local control 
rates of >90% was seen for HR CTV D90 larger than 85Gy, 89Gy and 
93Gy, respectively. There was no significant difference between dose 
response for HDR and PDR (p=0.113). There was a significant differ-
ence between SQ and AC+AdSq (p=0.02) with AC+AdSq being less 
favourable, in particular for lower doses. 
 
